PT - JOURNAL ARTICLE AU - Kaibiao Xu AU - Dongmei Wang AU - Yan He AU - Shengnan Wang AU - Guanghui Liu AU - Yue Pan AU - Haishan Jiang AU - Yu Peng AU - Fenliang Xiao AU - Yihua Huang AU - Qiqi Wang AU - Yongming Wu AU - Suyue Pan AU - Yafang Hu TI - Characterization of A Novel Autoimmune Encephalitis Associated Antibody against CRMP2 AID - 10.1101/2021.07.15.21260548 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.15.21260548 4099 - http://medrxiv.org/content/early/2021/07/25/2021.07.15.21260548.short 4100 - http://medrxiv.org/content/early/2021/07/25/2021.07.15.21260548.full AB - Objective Autoimmune encephalitis (AE) is a large category disorder urging antibody characterization. The aim was to identify a novel AE related autoantibody targeting an intracellular synaptic protein.Methods Suspected AE patients had negative conventional antibodies screening but strong immunolabel signals on rat brain sections with the serum and cerebrospinal fluid (CSF) samples were considered burdening unkown antibody.Immunoprecipitation from the rat brain protein lysate followed by mass spectrometry analysis was used to identify the targeting antigen. Western blotting and/or cell-based assay (CBA) with antigen-overexpressing HEK293T cells were used for antibody specificity, epitope and IgG subtype determination. Patients with similar immunostaining pattern on rat brain sections were retrospectively screened for the antibody.Results The antibody against collapsin response mediator protein 2 (CRMP2), a synaptic protein involved in axon guidance, was identified in a patient with suspected AE. The patient samples reactivated with HEK293T cell overexpressed CRMP2, rather than CRMP1, 3, 4, and 5. The patient samples mainly stained neuronal cytoplasm of the cortex, hippocampus and cerebellum Purkinje cells. This reactivity was eliminated by pre-immunoabsorption with CRMP2-overexpressing HEK293T cells. CRMP2 truncation experiments indicated that 536 amino acids at C-terminus was necessary for the epitope. Subtype analysis showed that anti-CRMP2 antibody was IgG4. Moreover, screening from 19 suspected AE patients led to identification of anti-CRMP2 antibody in another patient with a diagnosis of encephalomyelitis. The two patients responded to immunotherapy.Conclusions This study discovered a novel anti-CRMP2 antibody associated with AE. Testing of the antibody might be promising for AE diagnosis and treatment.Competing Interest StatementA patent (202110461611.6) is pending for the assay to detect the anti-CRMP2 antibody in autoimmune encephalitis (S.Y.P., Y.F.H., S.N.W., G.H.L., D.M.W., K.B.X., Y.M.W.). No other disclosures to report.Funding StatementThis work was supported by the National Natural Science Foundation of China (81771225 to Y.F.H., 82071484 to Y.M.W.), Guangdong Provincial Scientific and Technologic Progression Fund (2016A020215182 to Y.F.H.), Natural Science Foundation of Guangdong Province (2019A1515011760 to Y.M.W.), President Foundation of Nanfang Hospital (2019B007 to D.M.W., 2020B008 to K.B.X.), Medical Science and Technology Foundation of Guangdong Province (A2021151 to K.B.X.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Review Committee of Nanfang hospital, the Southern Medical University, Guangzhou, China.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. Anonymised data used in the present study may be available upon reasonable request to the corresponding author Y.F.H..